JP2007511516A5 - - Google Patents

Download PDF

Info

Publication number
JP2007511516A5
JP2007511516A5 JP2006539843A JP2006539843A JP2007511516A5 JP 2007511516 A5 JP2007511516 A5 JP 2007511516A5 JP 2006539843 A JP2006539843 A JP 2006539843A JP 2006539843 A JP2006539843 A JP 2006539843A JP 2007511516 A5 JP2007511516 A5 JP 2007511516A5
Authority
JP
Japan
Prior art keywords
beneficial agent
administration
anesthetics
anesthetic
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006539843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511516A (ja
Filing date
Publication date
Priority claimed from US10/985,116 external-priority patent/US20050281879A1/en
Application filed filed Critical
Publication of JP2007511516A publication Critical patent/JP2007511516A/ja
Publication of JP2007511516A5 publication Critical patent/JP2007511516A5/ja
Pending legal-status Critical Current

Links

JP2006539843A 2003-11-14 2004-11-12 薬品送達ビヒクル中の賦形剤 Pending JP2007511516A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51997203P 2003-11-14 2003-11-14
US10/985,116 US20050281879A1 (en) 2003-11-14 2004-11-10 Excipients in drug delivery vehicles
PCT/US2004/037606 WO2005048989A1 (en) 2003-11-14 2004-11-12 Excipients in drug delivery vehicles

Publications (2)

Publication Number Publication Date
JP2007511516A JP2007511516A (ja) 2007-05-10
JP2007511516A5 true JP2007511516A5 (cg-RX-API-DMAC7.html) 2007-07-26

Family

ID=34623114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006539843A Pending JP2007511516A (ja) 2003-11-14 2004-11-12 薬品送達ビヒクル中の賦形剤

Country Status (14)

Country Link
US (1) US20050281879A1 (cg-RX-API-DMAC7.html)
EP (1) EP1691785A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007511516A (cg-RX-API-DMAC7.html)
KR (1) KR20060125748A (cg-RX-API-DMAC7.html)
AR (1) AR046842A1 (cg-RX-API-DMAC7.html)
AU (2) AU2004291077A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0416032A (cg-RX-API-DMAC7.html)
CA (1) CA2545913C (cg-RX-API-DMAC7.html)
IL (1) IL175601A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06005464A (cg-RX-API-DMAC7.html)
NO (1) NO20062781L (cg-RX-API-DMAC7.html)
PE (1) PE20050494A1 (cg-RX-API-DMAC7.html)
TW (1) TW200524631A (cg-RX-API-DMAC7.html)
WO (1) WO2005048989A1 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368126B2 (en) * 2002-11-06 2008-05-06 Guohua Chen Controlled release depot formulations
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP2264162A1 (en) * 2005-07-02 2010-12-22 Arecor Limited Stable aqueous systems comprising proteins
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
AU2013202598B2 (en) * 2005-09-30 2016-06-09 Durect Corporation Sustained release small molecule drug formulation
US8852638B2 (en) * 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US7261742B2 (en) 2005-10-13 2007-08-28 S.C. Johnson & Son, Inc. Method of deodorizing a textile
US7407922B2 (en) 2005-10-13 2008-08-05 S.C. Johnson & Son, Inc. Deodorizing compositions
CA2637569C (en) * 2006-01-18 2013-01-08 Yuhua Li Pharmaceutical compositions with enhanced stability
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
CN101677952B (zh) 2007-05-18 2012-12-05 杜雷科特公司 改进的贮库制剂
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
WO2009110939A2 (en) * 2007-12-10 2009-09-11 Massachusetts Institute Of Technology Drug delivery system for pharmaceuticals and radiation
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US8956642B2 (en) * 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US20100016808A1 (en) * 2008-07-17 2010-01-21 Bioform Medical, Inc. Thin-Walled Delivery System
ES2344674B1 (es) * 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013142996A1 (en) * 2012-03-30 2013-10-03 The Royal Institution For The Advancement Of Learning/Mcgill University Magnesium phosphate gels
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
WO2014164754A1 (en) 2013-03-11 2014-10-09 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US20160128997A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Sustained-release buprenorphine formulations
HK1246641A1 (zh) * 2015-03-18 2018-09-14 参天制药株式会社 缓释性医药组合物
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
JP6872322B2 (ja) * 2015-07-01 2021-05-19 参天製薬株式会社 クエン酸エステルを含有するデポ剤
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
CN105295310A (zh) * 2015-11-11 2016-02-03 苏州国泰科技发展有限公司 一种绿色环保型增塑剂
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US630200A (en) * 1899-03-13 1899-08-01 Draper Co Warp-stop-motion mechanism.
US4443340A (en) * 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US4985404A (en) * 1984-10-04 1991-01-15 Monsanto Company Prolonged release of biologically active polypeptides
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
WO1993017668A1 (en) * 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
JPH08503950A (ja) * 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
EP1125577B1 (en) * 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
US5801012A (en) * 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
ATE318580T1 (de) * 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
JP3077635B2 (ja) * 1997-06-20 2000-08-14 日本電気株式会社 高速無線アクセス装置
EP1140289A1 (en) * 1998-12-18 2001-10-10 Angiosonics Inc. Method for prevention and treatment of cancer and other cell proliferative diseases with ultrasonic energy
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
WO2002089849A1 (en) * 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
AU2002359407B2 (en) * 2001-11-14 2008-02-28 Durect Corporation Catheter injectable depot compositions and uses thereof
ATE507816T1 (de) * 2001-11-14 2011-05-15 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung
NZ533434A (en) * 2001-11-14 2006-11-30 Alza Corp Thixotropic gel composition for injectable deposition
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles

Similar Documents

Publication Publication Date Title
US10765677B2 (en) Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
ES2270335T3 (es) Composicion farmaceutica de efecto rapido.
JP5786195B2 (ja) 舌下フィルム
ES2237104T3 (es) Dispositivo portador de productos farmaceuticos adecuado para el aporte de compuestos farmaceuticos a superficies mucosas.
IL174562A0 (en) Oros push-stick for controlled delivery of active agent
JP2006522149A5 (cg-RX-API-DMAC7.html)
JP2010533225A5 (cg-RX-API-DMAC7.html)
CA2531833A1 (en) Poly-4-hydroxybutyrate matrices for sustained drug delivery
DK1740154T3 (da) Insulinsammensætninger med forbedret absorption
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
US20210308040A1 (en) Ketamine oral transmucosal delivery system
ATE432689T1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
JP2006512324A5 (cg-RX-API-DMAC7.html)
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
UA83320C2 (ru) Таблетка для рассасывания, содержащая октенидин и предназначенная для лечения воспалительных заболеваний полости рта и глотки
JP2008534503A5 (cg-RX-API-DMAC7.html)
JP2005521662A (ja) プロトンポンプ阻害剤の経粘膜送達
BRPI0519022A2 (pt) formaÇço insitu de implante para animais
JP3515761B2 (ja) 義歯用口腔湿潤剤
JP6959313B2 (ja) 口腔内貼付剤
TWI351957B (en) Prolonged-release diuretic compositions
JP2004136102A (ja) 義歯用口腔湿潤剤
US8758804B2 (en) Controlled and continued delivery of rifaximin and/or other substances
Maffei et al. Design and in vitro-in vivo evaluation of a bi-layered tablet containing benzocaine for local buccal administration